Regulation of APP Processing by Par-4
Par-4 对 APP 处理的规定
基本信息
- 批准号:6986751
- 负责人:
- 金额:$ 16.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-12-01 至 2007-11-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseamyloid proteinsapoptosiscalcium fluxcell growth regulationenzyme linked immunosorbent assaygel electrophoresisgene targetinggenetically modified animalsimmunoprecipitationlaboratory mouseneoplastic cell culture for noncancer researchneuronsnorthern blottingspolymerase chain reactionposttranslational modificationsprotein biosynthesisprotein protein interactionprotein structureprotein structure functionwestern blottings
项目摘要
DESCRIPTION (provided by applicant): We recently identified the leucine zipper protein Par-4 (prostate apoptosis response-4) as a novel cell death promoting protein associated with pathogenesis of Alzheimer's disease (AD). Importantly, we have found that Par-4 may participate in regulation of Abeta production through a caspase-dependent pathway in transfected IMR-32 cells (Guo Q. et al., Nature Medicine 1998; 4(8): 957-962, Guo Q. et al., J. Biol. Chem., 2001; 276: 16040-4). Disruption of intracellular calcium homeostasis may lead to aberrant induction of Par-4 and abnormal processing of beta amyloid precursor protein (APP). These data suggest that Par-4 may be a novel regulator of APP processing. Most recently, we found that Par-4 interacts directly with APP, and alter Abeta secretion. These data strongly indicate that Par-4 regulates APP processing by at least two different mechanisms: (a) by caspase- and calcium-dependent pathways that is activated during apoptotic process, and (b) through direct physical interaction with APP. AATF is a novel leucine zipper protein that is expressed in neurons. We found AATF binds directly to Par-4 and confers neuroprotective actions, indicating that AATF might be an endogenous regulator of Par-4 activity. The proposed studies will employ a series of in vitro and in vivo approaches to test the following hypotheses: (1) Par-4 plays an essential role in aberrant APP processing of APP after initiation of apoptotic cascades; (2) Par-4 alters APP processing during apoptosis through a calcium-dependent pathway; (3) Par-4 directly interacts with APP and alters intracellular Abeta production and/or extracellular pool of secreted APPs and Abeta under apoptotic and/or nonapoptotic conditions; (4) AATF is a novel interaction partner of Par-4 and functions as an endogenous negative regulator of Par-4 activity in APP processing. The proposed studies may establish Par-4 as a novel regulator of APP processing. Inhibition of Par-4 activity by enhancing AATF expression and/or manipulating Par-4/APP interaction may provide novel therapeutic implications for Alzheimer's disease.
描述(由申请人提供):我们最近鉴定了亮氨酸拉链蛋白Par-4(前列腺凋亡反应-4)作为与阿尔茨海默病(AD)发病机制相关的新的细胞死亡促进蛋白。重要的是,我们已经发现Par-4可以通过转染的IMR-32细胞中的半胱天冬酶依赖性途径参与调节Abeta产生(Guo Q.例如,Nature Medicine 1998; 4(8):957-962,Guo Q.例如,J. Biol. Chem.,2001; 276:16040-4)。细胞内钙稳态的破坏可能导致Par-4的异常诱导和β淀粉样前体蛋白(APP)的异常加工。这些数据表明,Par-4可能是APP加工的一种新的调节剂。最近,我们发现Par-4直接与APP相互作用,并改变Abeta分泌。这些数据强烈地表明Par-4通过至少两种不同的机制调节APP加工:(a)通过在凋亡过程中被激活的半胱天冬酶和钙依赖性途径,以及(B)通过与APP的直接物理相互作用。AATF是在神经元中表达的新型亮氨酸拉链蛋白。我们发现AATF直接与Par-4结合并赋予神经保护作用,表明AATF可能是Par-4活性的内源性调节剂。本研究将采用一系列的体内外实验方法来验证以下假设:(1)Par-4在APP的异常加工过程中起重要作用:(2)Par-4通过钙依赖性途径改变APP在凋亡过程中的加工;(3)Par-4直接与APP相互作用,并在凋亡和/或非凋亡条件下改变细胞内A β的产生和/或分泌的APP和A β的细胞外库;(4)AATF是Par-4的一种新的相互作用伙伴,在APP加工过程中起着Par-4活性的内源性负调节剂的作用。拟议的研究可能建立Par-4作为APP加工的新调节剂。通过增强AATF表达和/或操纵Par-4/APP相互作用来抑制Par-4活性可能为阿尔茨海默病提供新的治疗意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
QING GUO其他文献
QING GUO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('QING GUO', 18)}}的其他基金
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 16.99万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 16.99万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 16.99万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 16.99万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 16.99万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 16.99万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 16.99万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 16.99万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 16.99万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 16.99万 - 项目类别:














{{item.name}}会员




